Biosimilar Medicines: Creating Sustainable Competition in an Era of a New Patent Cliff in Biological Medicines

Journal of Pharmaceutical Policy and Practice - United Kingdom
doi 10.1186/2052-3211-8-s1-p28
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cross-National Comparison of Biosimilar Medicines : Market Penetration and Competition With Originators

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Patent Medicines and Advertisers

American Journal of Public Health and the Nations Health
1938English

A Critique of an Argument Against Patent Rights for Essential Medicines

Ethics and Global Politics
SociologyInternational RelationsPolitical Science
2014English

Benefits and Drawbacks of Moving to Biosimilar Medicines

Prescriber
Pharmacology
2019English

European Medicines Agency Workshop on Biosimilar Monoclonal Antibodies

mAbs
AllergyImmunology
2009English

DNA Based Identification of Medicinal Materials in Chinese Patent Medicines

Scientific Reports
Multidisciplinary
2012English

Influence of Biosimilar Infliximab Launch on the Utilization Pattern of Biological Medicines: The Case of Hungary

Expert Review of Pharmacoeconomics and Outcomes Research
MedicineHealth PolicyPharmacology
2019English

Towards a Patent Pool for HIV Medicines: The Background

Open AIDS Journal
EnvironmentalPublic HealthInfectious DiseasesVirologyOccupational Health
2010English

Php22 - Is the European Biosimilar Medicines Market Becoming Unsustainable? An Exploration of the Combined Impact of Competition, Interchangeability, Procurement, and Pricing

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy